Glyxambi tabs granted FDA approval

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. on Monday announced that the Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets. The medicine is to be used as an adjunct to diet and excercise to improve blood sugar levels in adults with type 2 diabetes.

 

Glyxambi — which combines 10 mg or 25 mg of empagliflozin with 5 mg of linagliptinis — is the first and only treatment for diabetes in the United States that combines the actions of sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor in a once-daily tablet, according to the companies. 

 

"Today's medical community recognizes the need to treat type 2 diabetes from multiple fronts to help patients improve glycemic control," said Paul Fonteyne, president and CEO of BIPI. "With GLYXAMBI, the dual inhibition of DPP-4 and SGLT2 — two proven targets in the treatment of type 2 diabetes — now provides U.S. physicians and patients with an option to simultaneously address multiple pathways to improve glycemic control."

 

Glyxambi is not recommended for patients with type 1 diabetes or to treat diabetic ketoacidosis.